Article Contents ::
- 1 The Brand Name NIVAQUIN-P Has Generic Salt :: Chloroquine
- 2 NIVAQUIN-P Is From Company Piramal Hc. Priced :: Rs. 6.04
- 3 NIVAQUIN-P have Chloroquine is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name NIVAQUIN-P Has Generic Salt :: Chloroquine
NIVAQUIN-P Is From Company Piramal Hc. Priced :: Rs. 6.04
NIVAQUIN-P have Chloroquine is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Chloroquine||F. TAB||Rs. 6.04||10|
Indications for Drugs ::
Rheumatoid arthritis, Malaria, Systemic lupus erythematosus, SLE, Amoebiasis
Drug Dose ::
Adult: PO Acute malaria As base: Initial: 600 mg, then 300 mg 6-8 hr later on day 1. Continue w/ 300 mg/day on days 2 and 3. Malaria prophylaxis As base: 300 mg/wk, starting 1 wk before exposure, continue throughout on a wkly basis and for at least 4 wk after exposure. Discoid and SLE; Rheumatoid arthritis As base: Initial: 150 mg/day. Max: 2.5 mg/kg/day. Hepatic amoebiasis As base: W/ emetine or dehydroemetine: 600 mg/day for 2 days then 300 mg/day for 2-3 wk. IV Severe malaria As base: 25 mg/kg given in several infusions over 30-32 hr.
Hypersensitivity, known or suspected resistant P. falciparum infection, porphyria, retinal damage, concurrent hepatotoxic drugs.
Drug Precautions ::
Psoriasis, diseases of the haematopoietic or CNS systems, myasthenia gravis, hepatic or renal impairment, G6PD deficiency, epilepsy, childn. Pregnancy and lactation. Slow infusion is used upon IV admin to prevent cardiotoxicity.
Drug Side Effects ::
Retinopathy, hair loss, photosensitivity, tinnitus, myopathy (long-term therapy). Psychosis, seizures, leucopenia and rarely aplastic anaemia, hepatitis, GI upsets, dizziness, hypokalaemia, headache, pruritus, urticaria, difficulty in visual accommodation. Potentially Fatal: Cardiac and respiratory arrest, CV collapse, convulsions, coma.
Pregnancy category ::
Drug Mode of Action ::
Chloroquine is used for malarial prophylaxis (as a suppressive) and in managing acute attacks of malaria. It is highly active against erythrocytic forms of P. vivax, P. malariae and P. falciparum. It influences Hb digestion by increasing intravesicular pH in malaria parasite cells and interferes with the nucleoprotein synthesis of the patient. It is also effective in extra intestinal amoebiasis. In RA chloroquine and more effectively hydroxychloroquine have a disease-modifying effect.
Drug Interactions ::
Concomitant therapy with phenylbutazone predisposes to dermatitis, antagonises effect of neostigmine and pyridostigmine, reduces bioavailability of ampicillin. Cimetidine inhibits metabolism of chloroquine raising plasma levels. Potentially Fatal: Increased risks of inducing ventricular arrhythmias with halofantrine or other arrhythmogenic drugs eg, amiodarone. Increased risk of convulsions with mefloquine. Antacids reduce absorption of chloroquine hence admin should be separated by 4 hrs. Rarely Stevens-Johnson syndrome, when administered with pyrimethamine/sulphadoxine. Increased toxicity with quinacrine